Comprehensive medication guide to Strattera including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$30 copay per 30-day supply for generic atomoxetine, typically placed at Tier 2 on most commercial plans and Medicare Part D. Prior authorization may be required for adults age 21+; step therapy requiring a stimulant trial first is common on some plans.
Estimated Cash Pricing
$15–$60 per 30-day supply for generic atomoxetine with a GoodRx or SingleCare coupon; retail price without discount is $300–$460. Brand-name Strattera was discontinued in November 2023 and is no longer available.
Medfinder Findability Score
78/100
Summarize with AI
On this page
Atomoxetine, formerly sold as the brand name Strattera, is a prescription medication used to treat attention deficit hyperactivity disorder (ADHD) in children ages 6 and older, adolescents, and adults. It was FDA-approved on November 26, 2002, becoming the first non-stimulant medication ever approved for ADHD in the United States.
Unlike stimulant ADHD medications such as Adderall (amphetamine) and Ritalin (methylphenidate), atomoxetine is not a controlled substance. It belongs to the drug class of selective norepinephrine reuptake inhibitors (sNRIs) and has no abuse potential. This makes it a preferred option for patients who cannot use stimulants due to substance use history, anxiety disorders, cardiac concerns, or professional reasons.
Eli Lilly discontinued brand-name Strattera in November 2023 due to declining sales after generics entered the market in 2017. Generic atomoxetine is now widely available from multiple manufacturers including Teva, Aurobindo, Zydus, Hikma, and others. The generic is therapeutically equivalent to the original brand.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Atomoxetine works by selectively blocking the presynaptic norepinephrine transporter (NET) in the brain. The NET normally "vacuums up" norepinephrine after it is released at synapses — a process called reuptake. By blocking the NET, atomoxetine keeps norepinephrine in the synapse longer, enhancing signaling between neurons.
This effect is concentrated in the prefrontal cortex (PFC), the brain region responsible for executive function, attention, working memory, and impulse control. Because the NET also handles dopamine reuptake in the PFC, atomoxetine indirectly increases dopamine levels there as well — improving both norepinephrine and dopamine signaling specifically in attention-related circuits.
Unlike stimulants, which rapidly flood the brain with dopamine throughout all reward centers (creating the characteristic stimulant "rush" and abuse potential), atomoxetine's effect is gradual and selective. This is why it takes 4–8 weeks to reach full therapeutic effect, but it also explains why it has no abuse potential and provides 24-hour symptom coverage from a once-daily dose.
10 mg — capsule
Starting dose for small children; weight-based dosing 0.5 mg/kg/day
18 mg — capsule
Pediatric dosing step-up strength
25 mg — capsule
Pediatric and small adult dosing
40 mg — capsule
Standard starting dose for adults and children over 70 kg
60 mg — capsule
Intermediate dose for dose titration
80 mg — capsule
Standard target dose for adults (80 mg/day)
100 mg — capsule
Maximum daily dose for adults; may be used if 80 mg is insufficient after 2–4 weeks
Generic atomoxetine is not on the FDA's active drug shortage list as of 2026, and is generally easier to find than stimulant ADHD medications (Adderall, Vyvanse, Ritalin) which have faced prolonged national shortages. Multiple manufacturers supply the market, providing supply chain resilience.
However, individual pharmacies can still experience localized stock gaps — particularly for specific doses or in areas where Glenmark was the primary supplier before their January 2025 recall of approximately 1.48 million bottles. Higher doses (80 mg, 100 mg) at smaller pharmacies may be harder to find. The brand-name Strattera is no longer available anywhere, having been discontinued in November 2023.
If your pharmacy is out of stock, medfinder calls pharmacies near you to find which ones have your exact dose in stock, then texts you the results. No hold music, no calling around yourself.
Because atomoxetine is not a controlled substance, any licensed healthcare provider who can write prescriptions is legally permitted to prescribe it — with no special DEA registration or monthly prescription requirements. This makes it significantly more accessible than Schedule II stimulant ADHD medications.
Psychiatrists — specialists in complex ADHD and comorbid psychiatric conditions
Primary care physicians (PCPs) / Family medicine doctors — can diagnose and treat ADHD and prescribe atomoxetine for adults
Pediatricians — primary prescribers for children ages 6+ with ADHD
Neurologists — may treat adult ADHD, particularly with neurological comorbidities
Nurse practitioners (NPs) and physician assistants (PAs) — can prescribe in most states (scope of practice varies by state)
Atomoxetine is widely available via telehealth. Because it is not a controlled substance, a standard telehealth video visit is legally sufficient for evaluation and prescribing in all 50 states. Platforms including Doctor on Demand, Klarity Health, ADHD Advisor, and others offer same-day or next-day ADHD evaluations with atomoxetine prescribing when medically appropriate.
No. Atomoxetine (Strattera) is not a controlled substance and is not listed under any DEA schedule. This is one of its key distinguishing features from most other ADHD medications.
The practical implications for patients are significant: prescriptions can be refilled without a new written prescription each month, 90-day supplies are permitted, telehealth prescribing is allowed in all 50 states without an in-person visit requirement (the Ryan Haight Act does not apply), and there are no legal barriers to mail-order dispensing.
Clinical studies of atomoxetine have consistently shown a lack of abuse potential, consistent with its mechanism — unlike stimulants, it does not significantly increase dopamine in the brain's reward centers. Patients can also stop taking atomoxetine without tapering, unlike alpha-agonists (guanfacine, clonidine) which require gradual dose reduction.
The most common side effects include:
Decreased appetite and nausea (most common; take with food to reduce)
Headache, especially in the first few weeks
Drowsiness and fatigue
Dizziness, especially when standing up quickly
Dry mouth and constipation
Mood swings and irritability (particularly early in treatment)
Sexual side effects in adults (decreased libido, erectile dysfunction)
Suicidal ideation: Black box warning; risk elevated in children and adolescents, especially in first months of treatment
Liver damage: Jaundice, dark urine, right upper abdominal pain — stop medication and seek care immediately
Heart problems: Chest pain, fainting, rapid heartbeat, stroke symptoms
Psychosis or mania: Hallucinations, delusions, manic episodes — especially in people without prior psychiatric history
Severe allergic reaction: Hives, swelling of face/throat, difficulty breathing
Know what you need? Skip the search.
Qelbree (viloxazine ER)
Closest alternative — also a selective sNRI; FDA-approved ages 6+; may show effect in 2–4 weeks vs 4–8 weeks; no generic available; once-daily dosing; capsule can be opened and sprinkled on food
Intuniv (guanfacine ER)
Alpha-2 adrenergic agonist; different mechanism; FDA-approved ages 6–17; generic available; more sedating than atomoxetine; requires gradual tapering to discontinue
Kapvay (clonidine ER)
Alpha-2 adrenergic agonist; most sedating non-stimulant option; FDA-approved ages 6–17; generic available; can help with ADHD-related sleep difficulties
Wellbutrin (bupropion)
Off-label for ADHD; NDRI antidepressant; particularly useful for adults with comorbid depression; generic widely available; not FDA-approved for ADHD
Prefer Strattera? We can find it.
MAOIs (phenelzine, tranylcypromine, selegiline, etc.)
majorContraindicated — can cause life-threatening hypertensive crisis. Do not use within 2 weeks of each other.
Fluoxetine (Prozac)
majorStrong CYP2D6 inhibitor that can double atomoxetine plasma levels. Start atomoxetine at 40 mg/day; max 80 mg/day when combined.
Paroxetine (Paxil)
majorStrong CYP2D6 inhibitor with same effect as fluoxetine. Requires dose adjustment and monitoring.
Quinidine
majorPotent CYP2D6 inhibitor; can significantly increase atomoxetine levels.
Bupropion (Wellbutrin)
moderateModerate CYP2D6 inhibitor; can increase atomoxetine exposure. Monitor for increased side effects.
Albuterol and beta-agonists
moderateAdditive cardiovascular effects (increased heart rate/blood pressure). Use with caution; inform prescriber.
QT-prolonging medications (antipsychotics, azithromycin, methadone)
moderateAdditive QT interval prolongation risk. ECG monitoring recommended if co-administered.
Atomoxetine is a well-established, non-stimulant ADHD medication with over 20 years of clinical use. While the brand-name Strattera is gone (discontinued by Eli Lilly in 2023), the generic medication is widely available, highly affordable with the right discount tools (as low as $15/month with GoodRx), and continues to provide effective ADHD treatment for millions of patients.
Atomoxetine's non-controlled status, telehealth accessibility, lack of abuse potential, and 24-hour coverage make it the first-choice non-stimulant for many patients — particularly those with substance use history, significant anxiety, or who prefer to avoid controlled substances. Its primary limitation is the 4–8 week onset time, which requires patient education and commitment to consistent daily dosing.
If you have a prescription but are having trouble finding atomoxetine at your local pharmacy, medfinder can help — we call pharmacies near you to find which ones have your exact dose in stock, then text you the results so you don't have to.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini